

[Click here to view linked References](#)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

New frontiers in prostate cancer imaging: clinical utility of Prostate Specific Membrane Antigen Positron Emission Tomography

Asim Afaq^{1,2} , Deepak Batura^{3*}, Jamshed Bomanji¹

1. Institute of Nuclear Medicine, University College London Hospitals
NHS Foundation Trust, Euston Road, London, UK
2. Department of Radiology, London North West Healthcare NHS Trust,
Watford Road, London, UK
3. Department of Urology, London North West Healthcare NHS Trust,
Watford Road, London, UK

34 *Corresponding author:

35
36 Deepak Batura

37
38 Department of Urology,

39
40 London North West Healthcare NHS Trust

41
42 Watford Road, London, UK

43
44
45
46 deepakbatura@gmail.com

47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Abstract

Prostate specific membrane antigen Positron Emission Tomography (PSMA PET) is a relatively new method of imaging prostate cancer that increases diagnostic accuracy in detecting and guiding management in various stages of the disease pathway.

Gallium -68 labelled PSMA PET has increased the sensitivity of detection of disease recurrence at low PSA levels, thus allowing an optimal window for salvage treatment.

Apart from its use in disease recurrence, PSMA PET has the potential for increasing sensitivity and specificity for primary tumour localisation and in detecting lymph node disease, leading to a more accurate initial staging of the condition.

In advanced disease, the use of PSMA PET may be able to assess response to treatment and also guide treatment with radionuclide therapy. Newer ligands under development might provide avenues for theranostic or personalised therapy applications with early data showing high PSA response rates.

The rate of translation of PSMA PET into clinical practice has been remarkable. The use of this modality is likely to increase with future efforts to modify the radiotracer including ^{18}F labelling to improve availability.

Keywords

PSMA PET, Prostate cancer, imaging, theranostics, radiotracers

Introduction

The diagnosis and management of prostate cancer (PCa) is widely dependent on imaging tools to achieve accuracy and precision. Currently, many centres rely on multiparametric MRI (mpMRI) and planar bone scintigraphy as the most often used imaging modalities. Despite advances in imaging, the diagnosis and follow-up of PCa continue to remain challenging. Positron emission tomography (PET) CT has had an increasing role in PCa management in recent years with the availability of ^{11}C and ^{18}F choline tracers. ^{11}C has a short half-life of 20 minutes requiring the presence of a cyclotron on site for synthesis and ^{18}F has a half-life of approximately 110 minutes. The short half-life of ^{11}C limits its distribution and utility. Moreover, Choline PET suffers from limited sensitivity in detecting disease at low PSA levels [1]. These limitations, in turn, have led to the search for newer PET tracers and imaging biomarkers to help increase sensitivity and accuracy of imaging in PCa detection.

Prostate Specific Membrane Antigen (PSMA) is a type II transmembrane glycoprotein, typically associated with the apical membrane, with transfer to the ductal luminal surface in prostate tissue and highly expressed on the surface of prostate tumour cells [2]. When used as a target for PET imaging with Gallium 68 (^{68}Ga) labelling, the normal physiological distribution includes salivary glands and the kidneys which demonstrate relatively intense tracer uptake, and the lacrimal glands, liver, spleen and the intestines which have moderate activity. Excretion of unbound tracer occurs via the urinary tract [3]. PCa causes a massive overexpression of PSMA in tumour tissue, allowing radiolabeled agents targeting this protein a greater sensitivity in tumour

1 detection. However, non-prostatic tumours also demonstrate PSMA
2 expression in areas of neovascularity including renal, bladder, breast and
3 colon cancer [4-9]. Despite expression seen on other sites, PSMA has been
4 developed as a radiotracer and has entered into clinical practice as a
5 biomarker for the detection of PCa and its metastases.
6
7

8
9
10
11 ⁶⁸Ga-PSMA is produced using a 68 Germanium (Ge)/⁶⁸Ga radionuclide
12 generator. After injecting 1.8-2.2MBq/kg body weight as an IV bolus, PET
13 acquisition begins approximately 60 minutes after tracer injection. Depending
14 on scanner specifications, there are variations in the length of time needed for
15 each bed position (body section typically divided into four, beginning at the
16 mid thighs and moving towards the vertex), but in modern scanners, 3-
17 4minutes per bed position is typical. Following this, a low dose CT scan
18 images the same volume for attenuation correction and anatomic localisation.
19 The technique can vary in numerous ways to improve image quality, including
20 using iv iodinated contrast medium with the CT, administering a diuretic
21 (frusemide) at the time of radiotracer injection and rectal filling with a negative
22 contrast medium [10].
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40

41 **Applications of PSMA PET in biochemical recurrence of PCa**

42
43 PCa patients who have had radical prostatectomy or radiotherapy have a risk
44 of developing recurrent disease, defined by a rise in serum PSA, with
45 specified criteria in the context of previous treatment. Once PCa recurrence is
46 suspected, the search for disease begins with subsequent management
47 dependent on metastatic extent. Recurrence may be in the prostate or
48 prostatectomy bed, within pelvic or more remote lymph nodes, within the
49 skeletal system or other less common distributions including lung and soft
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 tissue deposits. Detection of localised disease at low PSA levels allows an
2 optimal range of treatment strategies to be offered, particularly essential as
3 salvage radiotherapy in recurrence post-prostatectomy is most effective at
4 serum PSA <0.5ng/ml [11,12].
5
6
7

8
9 Disease assessment in the context of biochemical recurrence forms the bulk
10 of literature in the use of ⁶⁸Ga-PSMA PET. The clinical need for a sensitive
11 tool for early detection of recurrence exists because current modalities
12 struggle to identify disease at a low PSA level successfully. For example,
13 choline PET tracers have a detection rate ranging from 19-36% when serum
14 PSA is below 1.5ng/mL [13,14,15]. (Fig 1)
15
16
17
18
19
20
21
22
23

24 Published studies on imaging in this clinical setting have suffered from the
25 limitation of lack of histological correlation of most sites determined positive
26 for the disease by imaging, as this would be impractical in many cases. When
27 compared with choline PET, PSMA was found to be superior in disease
28 detection in 37 patients. PSMA PET was able to detect all PCa lesions
29 demonstrated on Choline PET as well as additional sites of tumour, identifying
30 86.5% of patients with at least one site of disease characteristic for PCa
31 compared with 70.3% with Choline PET [16]. Similarly, Morigi et al. have
32 shown findings of ⁶⁸Ga-PSMA superiority over choline in 38 patients, where
33 on lesion-based analysis, ⁶⁸Ga-PSMA detected significantly more lesions than
34 (18)F-fluoromethylcholine (59 vs. 29 respectively, P < 0.001) [17]. (Fig 2).
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 The first large patient cohort study involved 319 patients with biochemical
52 recurrence. In this study, 82.8% of ⁶⁸Ga-PSMA scans were positive, and the
53 probability of detecting disease increased with higher PSA levels. For
54 example, there was a 50% likelihood of positive scan at PSA <0.5 and 60%
55
56
57
58
59
60
61
62
63
64
65

1 when PSA was 0.5-1 [18]. This study showed no significant association of
2 positive scans with PSA doubling times, although a tendency towards positive
3 scans with unfavourable PSA kinetics was noted. Others have shown a
4 significant relationship correlation, although less marked than the correlation
5 with PSA [19].
6
7
8
9

10 There is evidence from preclinical studies that higher Gleason grade tumours
11 express more PSMA receptors and would help explain why a higher Gleason
12 score correlates with positive PSMA imaging [20].
13
14
15
16
17
18

19 **Impact on primary staging**

20 Multiparametric MRI is the gold standard of imaging based staging of primary
21 prostate cancer. The combination of T2 sequences, diffusion weighted
22 imaging and dynamic contrast enhancement has become widely used with a
23 1-5 score (PIRADS) of confidence of tumour detection. However, the
24 accuracy in detecting disease on MRI reduces with small volume or low grade
25 (Gleason 3+3) disease [21, 22]. Recently, ⁶⁸Ga-PSMA has been evaluated in
26 simultaneous PET and MRI scanners and has shown to be of use in detecting
27 disease, with complimentary findings from both modalities. Although very
28 limited data exists on the use of primary tumour evaluation, initial reports have
29 suggested potential key benefits of PSMA including a lack of influence of
30 uptake in the post-biopsy setting compared to MRI. Prostatic tumour foci were
31 predicted correctly in 92.9% of high-risk prostate cancer patients undergoing
32 radical prostatectomy [23]. However, a potential limitation is that up to 10% of
33 primary prostate tumours may be PSMA negative, although no data exists to
34 establish the receptor status of tumour cells in these patients. Recognised
35 potential sources for false negative results include tumours located adjacent
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 to areas of high physiological tracer uptake, small tumours and those with
2 neuroendocrine differentiation seen in high grade and high stage disease[24].
3
4 Overall, there is an increase in sensitivity and specificity when using ⁶⁸Ga-
5 PSMA PET and mpMRI rather than using the modalities alone for primary
6
7 tumour localisation, especially when used in combination for guiding biopsy or
8
9 in the re-evaluation of cases where mpMRI alone has failed to identify the site
10
11 of disease. (Fig 3).
12
13
14
15

16 Previous studies have shown that up to 98% of lymph node metastases from
17
18 prostate cancer demonstrate very high levels of PSMA [25]. Promising results
19
20 have also been published recently using PSMA in nodal evaluation for initial
21
22 staging. In 130 patients with intermediate to high-risk prostate cancer treated
23
24 with prostatectomy and pelvic lymph node dissection, ⁶⁸Ga-PSMA was shown
25
26 to have a sensitivity of 65.9% and specificity of 98.9% for lymph node staging
27
28 [26]. These rates compare well with the reduced sensitivity of choline PET
29
30 (49.2%) with a similar high specificity of 95% and the even poorer sensitivity
31
32 and specificity for CT (42% and 82%) and MRI (39% and 82%) respectively
33
34 [27].
35
36
37
38
39

40 However, micrometastatic nodal disease may still escape detection. One
41
42 study retrospectively compared pre-operative ⁶⁸Ga-PSMA PET with
43
44 histological findings after radical prostatectomy. Lymph node metastases
45
46 were present in 12 out of 30 patients. ⁶⁸Ga-PSMA PET was found to have an
47
48 excellent specificity (100%) with no false positive findings“. ⁶⁸Ga-PSMA PET
49
50 could correctly identify only 4 of the 12 confirmed cases, although the size of
51
52 the histologically positive nodes not identified was significantly smaller (a
53
54 median histologically positive node size of 4.3mm not detected on PET,
55
56
57
58
59
60
61
62
63
64
65

1 compared to a median histologically positive node size of 13.6mm correctly
2 identified). The study had several limitations, not least a lack of involvement
3 from nuclear medicine specialists and a small sample size [23,28].
4

5 Furthermore, there was no proof that the nodes deemed false negative
6 contained tumour cells expressing PSMA receptors.
7

8 PSMA, therefore, appears to be the most accurate available method of
9 imaging based nodal assessment, with exciting potential future use in
10 combination with state of the art multiparametric MRI sequences.
11

12 Although planar bone scintigraphy has long been the standard for assessing
13 for bone metastases, whole-body MRI has been shown to be of superior
14 accuracy in bone metastasis detection [29]. The combination of PSMA with
15 whole body MRI, to detect nodal, bone and other sites of disease detection
16 offers a possible one-stop approach to staging, although extensive studies
17 including assessment of cost-effectiveness would be necessary to bring
18 forward such a move into clinical practice. (Fig 4).
19

20 A few studies have compared the diagnostic accuracy of ⁶⁸Ga-PSMA PET/CT
21 with ⁶⁸Ga-PSMA PET/MRI. In a study of 20 patients, Afshar-Oromieh, et al.
22 concluded prostate cancer diagnosis was easier and more accurate on
23 PET/MRI than PET/CT [30]. Unclear findings on PET/CT were able to be
24 clarified on PET/MR, although the latter were performed at a later uptake time
25 (three hours rather than an hour post injection) which may have aided disease
26 detection by increased tracer accumulation in the tumour over time [29].
27

28 Similarly, Freitag et al. demonstrated ⁶⁸Ga-PSMA PET/MR to be reliable and
29 accurate when compared to PET/CT for node and bone lesion detection in 26
30 patients [31].
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 Bone metastases tend to demonstrate less avid ^{68}Ga -PSMA uptake than
2 nodal sites of disease [32] However, lesions are still clearly positive on PET.
3
4 In a study evaluating 28 bone metastases with ^{68}Ga -PET/CT and PET/MRI,
5
6 two of these lesions were not demonstrated on the CT component of PET/CT
7
8 but were visible in the MR element, and all lesions were PET positive [31].
9
10

11 **Future trends**

12 Although ^{68}Ga -PSMA PET has rapidly entered clinical practice for use in the
13
14 setting of biochemical recurrence, there is a need for well-designed phase III
15
16 studies to prove this is best practice. Other potential uses will also require
17
18 further research as detailed below.
19
20
21
22

23 **Diagnostic and treatment applications in advanced disease**

24 In patients who have failed conventional therapy or have advanced metastatic
25
26 disease, PSMA may be able to guide other treatment options including
27
28 chemotherapy or radionuclide therapy.
29
30
31
32

33 Semiquantitative assessment of metastatic sites with metrics based on
34
35 Standardised Uptake Values (SUV) and metabolic tumour volume compared
36
37 with post therapy appearances may offer a method for assessing response to
38
39 treatment.
40
41
42

43 **Personalised therapy and theranostic applications**

44 PSMA ligands can be labelled with ^{188}Re (Rhenium) or ^{177}Lu (Lutetium) and
45
46 can act as a theranostic agent (providing diagnostic based therapy for
47
48 individual patients) for radio-guided surgery or endo-radiotherapy. Although
49
50 these agents are the subject of clinical trials, such compounds may be offered
51
52 currently under 'compassionate use' circumstances. Recent studies have
53
54 shown promising results with ^{177}Lu PSMA therapy, with a PSA response rate
55
56
57
58
59
60
61
62
63
64
65

1 of 80% after the first cycle in a study of 24 patients and 70% in another study
2 of 30 patients. However, the response may only be a short-term benefit in
3
4 some patients, with only 70% and 50% having an ongoing response in the
5
6 above two studies [33, 34].
7
8
9

10 11 **New agents**

12 As ^{68}Ga is generator produced, there is a movement towards developing a
13
14 suitable ^{18}F (Fluorine) labelled compound which could be mass produced via
15
16 cyclotron and become more widely available. Preliminary studies in humans
17
18 have demonstrated the feasibility of these tracers.
19
20
21

22 ^{18}F -DCFBC (N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-4-(^{18}F -fluorobenzyl-
23
24 L-cysteine ((^{18}F -DCFBC), is another radiotracer that targets PSMA. ^{18}F -
25
26 DCFBC has been evaluated and shown to identify more suspicious bone
27
28 lesions than bone scintigraphy or CT. This agent may also distinguish
29
30 between high and low-grade primary prostate lesions [35, 36].
31
32
33

34 A second generation ^{18}F labelled agent, ^{18}F -DCFPyL(2-(3-(1-carboxy-5-[(6-
35
36 [^{18}F]fluoro-pyridine-3-carbonyl)-amino]-pentyl)-ureido)-pentanedioic acid
37
38 ([^{18}F]DCFPyL) has been shown to demonstrate greater metastatic and
39
40 primary lesion conspicuousness than ^{18}F -DCFBC and also when compared
41
42 with ^{68}Ga -PSMA [37,38].
43
44
45

46 Future work may include modification of the PSMA molecule itself which could
47
48 alter function and increase sensitivity. Clearly, larger prospective studies
49
50 would be needed to confirm which form of PSMA ligand would be optimal for
51
52 clinical use.
53
54
55

56 57 **Conclusion**

58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

There is unequivocal evidence that ^{68}Ga -PSMA is highly sensitive and specific for prostate cancer disease detection, more so than any currently used imaging modalities and tracers and this has led to a rapid acceptance into clinical practice. PSMA PET has an important potential role in routine clinical management at multiple stages of the patient pathway. The commonest indication to date involves disease detection in the setting of biochemical recurrence although there may be opportunities for a role in initial disease evaluation and restaging or response assessment in advanced disease, with possible one-stop approaches using state of the art PET/MRI. Currently, ongoing clinical trial data have shown that PSMA ligands may also be labelled to act as theranostic agents, with initial data showing high rates of PSA response.

Acknowledgements: Dr Afaq is partly funded by the National Institute for Health Research University College London Hospitals Biomedical Research Centre and a London North West Healthcare Charitable Fund Grant.

Compliance with ethical standards

Conflict of interest: The authors declare they have no conflicts of interest in this study.

Ethical approval: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Human and animal rights: This article does not contain any studies with animals performed by any of the authors.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Informed consent: Informed consent was obtained from all individual participants included in the study.

References

1. Umbehre MH, Müntener M, Hany T, Sulser T, Bachmann LM (2013). The role of ¹¹C-choline and ¹⁸F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. *Eur Urol.* 64(1):106-117
2. Maurer T, Eiber M, Schwaiger M, Gschwend JE (2016). Current use of PSMA-PET in prostate cancer management. *Nat Rev Urol.* 13(4):226-235.
3. Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, Holland-Letz T, Giesel FL, Kratochwil C, Haufe S, Haberkorn U, Zechmann CM (2013). PET imaging with a [⁶⁸Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. *Eur J Nucl Med Mol Imaging.* 40(4):486-495.
4. Baccala A, Sercia L, Li J, Heston W, Zhou M (2007). Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms. *Urology.* 70(2):385–390.
5. Chang SS, Reuter VE, Heston WD, Gaudin PB (2001). Metastatic renal cell carcinoma neovasculature expresses prostate-specific membrane antigen. *Urology.* 57(4):801–805.
6. Chang S, Reuter V, Heston W, Bander N, Grauer L, Gaudin P (1999). Five different anti-prostate-specific membrane antigen (PSMA) antibodies conform PSMA expression in tumor-associated neovasculature. *Cancer Res.* 59(13):3192–3198.
7. Sathekge M, Modiselle M, Vorster M, Mokgoro N, Nyakale N, Mokaleng B, et al (2015). ⁶⁸Ga-PSMA imaging of metastatic breast cancer. *Eur J Nucl*

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Med Mol Imaging. 42(9):1482–1483.

8. Wernicke AG, Varma S, Greenwood EA, Christos PJ, Chao KS, Liu H, et al (2014). Prostate-specific membrane antigen expression in tumor-associated vasculature of breast cancers. *APMIS*. 122(6):482–489.

9. Nomura N, Pastorino S, Jiang P, Lambert G, Crawford JR, Gymnopoulos M, et al (2014). Prostate-specific membrane antigen (PSMA) expression in primary gliomas and breast cancer brain metastases. *Cancer Cell Int*. 14(1):26.

10. Rauscher I, Maurer T, Fendler WP, Sommer WH, Schwaiger M, Eiber M (2016). 68Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report. *Cancer Imaging*. 16(1):14.

11. Pfister D, Bolla M, Briganti A, Carroll P, Cozzarini C, Joniau S, van Poppel H, Roach M, Stephenson A, Wiegel T, Zelefsky MJ (2014). Early salvage radiotherapy following radical prostatectomy. *Eur Urol*. 65(6):1034-1043.

12. King CR (2012). The timing of salvage radiotherapy after radical prostatectomy: a systematic review. *Int J Radiat Oncol Biol Phys*. 84(1):104-111.

13. Castellucci P, Fuccio C, Rubello D, Schiavina R, Santi I, Nanni C, Allegri V, Montini GC, Ambrosini V, Boschi S, Martorana G, Marzola MC, Fanti S (2011). Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml? *Eur J Nucl Med Mol Imaging*. 38(1):55-63.

14. Castellucci P, Picchio M (2013). ¹¹C-choline PET/CT and PSA kinetics. *Eur J Nucl Med Mol Imaging*. 40 Suppl 1:S36-40.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
15. Graute V, Jansen N, Ubleis C, Seitz M, Hartenbach M, Scherr MK, Thieme S, Cumming P, Klanke K, Tiling R, Bartenstein P, Hacker M (2012). Relationship between PSA kinetics and [18F]fluorocholine PET/CT detection rates of recurrence in patients with prostate cancer after total prostatectomy. *Eur J Nucl Med Mol Imaging*. 39(2):271-282.
 16. Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, Holland-Letz T, Hadaschik BA, Giesel FL, Debus J, Haberkorn U (2014). Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. *Eur J Nucl Med Mol Imaging*. 41(1):11-20.
 17. Morigi JJ, Stricker PD, van Leeuwen PJ, Tang R, Ho B, Nguyen Q, Hruby G, Fogarty G, Jagavkar R, Kneebone A, Hickey A, Fanti S, Tarlinton L, Emmett L (2015). Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy. *J Nucl Med*. 56(8):1185-1190.
 18. Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, Eisenhut M, Boxler S, Hadaschik BA, Kratochwil C, Weichert W, Kopka K, Debus J, Haberkorn U (2015). The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. *Eur J Nucl Med Mol Imaging*. 42(2):197-209.
 19. Ceci F, Uprimny C, Nilica B, Geraldo L, Kendler D, Kroiss A, Bektic J, Horninger W, Lukas P, Decristoforo C, Castellucci P, Fanti S, Virgolini IJ (2015). (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? *Eur J Nucl Med Mol*

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Imaging. 42(8):1284-1294.

20. Ross JS, Sheehan CE, Fisher HA, Kaufman RP Jr, Kaur P, Gray K, Webb I, Gray GS, Mosher R, Kallakury BV (2003). Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. *Clin Cancer Res.* 9(17):6357-6362.

21. Turkbey B, Mani H, Shah V, Rastinehad AR, Bernardo M, Pohida T, Pang Y, Daar D, Benjamin C, McKinney YL, Trivedi H, Chua C, Bratslavsky G, Shih JH, Linehan WM, Merino MJ, Choyke PL, Pinto PA (2011). Multiparametric 3T prostate magnetic resonance imaging to detect cancer: histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds. *J Urol.* 186(5):1818-1824.

22. Styles C, Ferris N, Mitchell C, Murphy D, Frydenberg M, Mills J, Pedersen J, Bergen N, Duchesne G (2014). Multiparametric 3T MRI in the evaluation of intraglandular prostate cancer: correlation with histopathology. *J Med Imaging Radiat Oncol.* 58(4):439-448.

23. Budäus L, Leyh-Bannurah SR, Salomon G, Michl U, Heinzer H, Huland H, Graefen M, Steuber T, Rosenbaum C (2016). Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy. *Eur Urol.* 69(3):393-396.

24. Chakraborty PS; Tripathi M; Agarwal KK; Kumar R; Vijay MK; Bal C (2015). Metastatic poorly differentiated prostatic carcinoma with neuroendocrine differentiation: negative on 68Ga-PSMA PET/CT. *Clin Nucl Med.* 2015; 40(2):e163-6.

25. Sweat SD, Pacelli A, Murphy GP, Bostwick DG (1998). Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and

lymph node metastases. *Urology*. 52:637–640.

26. Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G, Wester HJ, Heck M, Kübler H, Beer AJ, Schwaiger M, Eiber M (2016).

Diagnostic Efficacy of (68)Gallium-PSMA Positron Emission Tomography Compared to Conventional Imaging for Lymph Node Staging of 130

Consecutive Patients with Intermediate to High Risk Prostate Cancer. *J Urol*. 195(5):1436-1443.

27. Evangelista, L., Guttilla, A., Zattoni, F., Muzzio, P. C. & Zattoni, F (2013).

Utility of choline positron emission tomography/computed tomography for lymph node involvement identification in intermediate- to high- risk prostate

cancer: a systematic literature review and meta-analysis. *Eur. Urol*. 63, 1040–1048.

28. Derlin T, Eiber M, Schwaiger M, Bengel FM (2016).Re: Lars Budäus,

Sami-Ramzi Leyh-Bannurah, Georg Salomon, et al. Initial Experience of (68)Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy. *Eur Urol* 2016;69:393-6. *Eur Urol*.70(2):e37-38.

29. Lecouvet FE, El Mouedden J, Collette L, Coche E, Danse E, Jamar F,

Machiels JP, Vande Berg B, Omoumi P, Tombal B (2012).Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? *Eur Urol*. 62(1):68-75.

30. Afshar-Oromieh A, Haberkorn U, Schlemmer HP, Fenchel M, Eder M,

Eisenhut M, Hadaschik BA, Kopp-Schneider A, Röthke M (2014).Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience. *Eur J Nucl*

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Med Mol Imaging. 41(5):887-897.

31. Freitag MT, Radtke JP, Hadaschik BA, Kopp-Schneider A, Eder M, Kopka K, Haberkorn U, Roethke M, Schlemmer HP, Afshar-Oromieh A (2016). Comparison of hybrid (68)Ga-PSMA PET/MRI and (68)Ga-PSMA PET/CT in the evaluation of lymph node and bone metastases of prostate cancer. Eur J Nucl Med Mol Imaging. 43(1):70-83.

32. Schmittgen TD, Teske S, Vessella RL, True LD, Zakrajsek BA (2003). Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients. Int J Cancer. 107:323–329.

33. Ahmadzadehfar H, Eppard E, Kürpig S, Fimmers R, Yordanova A, Schlenkhoff CD, Gärtner F, Rogenhofer S, Essler M. (2016). Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate- resistant metastatic prostate cancer. Oncotarget. 7:12477–12488.

34. Kratochwil C, Giesel FL, Stefanova M, Benešová M, Bronzel M, Afshar-Oromieh A, Mier W, Eder M, Kopka K, Haberkorn U (2016). PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA- 617. J Nucl Med. 57:1170–1176.

35. Cho SY, Gage KL, Mease RC, Senthamizhchelvan S, Holt DP, Jeffrey-Kwanisai A, Endres CJ, Dannals RF, Sgouros G, Lodge M, Eisenberger MA, Rodriguez R, Carducci MA, Rojas C, Slusher BS, Kozikowski AP, Pomper MG (2012). Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular- weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. J. Nucl. Med. 53, 1883–

1891.


1
2 36. Rowe SP, Gage KL, Faraj SF, Macura KJ, Cornish TC, Gonzalez-Roibon
3
4 N, Guner G, Munari E, Partin AW, Pavlovich CP, Han M, Carter HB,
5
6 Bivalacqua TJ, Blackford A, Holt D, Dannals RF, Netto GJ, Lodge MA, Mease
7
8 RC, Pomper MG, Cho SY (2015). F-DCFBC PET/CT for PSMA-based
9
10 detection and characterization of primary prostate cancer. *J. Nucl. Med.* 56 (7)
11
12 1003–1010.
13
14

15
16 37. Szabo Z, Mena E, Rowe SP, Plyku D, Nidal R, Eisenberger MA,
17
18 Antonarakis ES, Fan H, Dannals RF, Chen Y, Mease RC, Vranesic M,
19
20 Bhatnagar A, Sgouros G, Cho SY, Pomper MG (2015). Initial evaluation of
21
22 [F]DCFPyL for prostate-specific membrane antigen (PSMA)-targeted PET
23
24 imaging of prostate cancer. *Mol. Imaging Biol.* 17(4):565-574.
25
26

27
28 38. Dietlein M, Kobe C, Kuhnert G, Stockter S, Fischer T, Schomäcker K,
29
30 Schmidt M, Dietlein F, Zlatopolskiy BD, Krapf P, Richarz R, Neubauer S,
31
32 Drzezga A, Neumaier B (2016). Comparison of [F]DCFPyL and [68Ga]Ga-
33
34 PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate
35
36 cancer. *Mol. Imaging Biol.* 17(4), 575–584.
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65


1
2 **Figures**
3

4
5 Figure 1
6




45
46
47 This 66 year old man with Gleason 4+5 disease and previous prostatectomy
48 and radiotherapy had a rising PSA (1.9). ⁶⁸Ga-PSMA PET/CT showed small
49 volume PSMA avid retroperitoneal nodal recurrence. The solid arrow
50 demonstrates an avid node. The dashed arrows indicate physiological tracer
51 activity in the ureters.
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Figure 2a




A 68-year-old man with Gleason 4+4 disease treated with EBRT and then with salvage HIFU for recurrence in 2011. Now presenting with a rising PSA (29), Technetium99m methylene diphosphonate bone scintigraphy showed probable degenerative change at the right side of L3/4 and inferior aspect of the left sacroiliac joint (black arrows).

Figure 2 b



An ^{18}F Choline PET study (left image) showed possible disease in the left hemi-sacrum (black arrow), but no other sites of disease. Within a four-week interval, the patient had a ^{68}Ga -PSMA PET/CT (right, image) which confirmed left sacral disease (black arrow) but also demonstrated new metastases including the left 7th rib (long black arrow) and nodal sites (dashed arrows) as detailed in figure 2c.


Figure 2c



Axial fused images from the ^{68}Ga -PSMA PET/CT study showing retroperitoneal nodal disease (top left), right external iliac node (top right) and a posterior mediastinal node (bottom left)


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Figure 2d




Axial fused ^{68}Ga -PSMA PET/CT images showing left 7th rib disease (top image) and left sacral ala disease (bottom image).

Figure 3



This 72-year-old man underwent initial MRI assessment for elevated PSA of 22. (September 2015). Artefacts from the right hip prosthesis rendered diffusion and dynamic contrast enhanced images non-diagnostic; however, there was a possibility of disease in the right TZ (white arrow on the left image, axial T2 small field of view MRI image). In Feb 2016, a prostate biopsy revealed Gleason 3+4 disease with a focus of 5. PSMA PET (March 2016) revealed tracer-avid tumour in the right TZ but no other sites of disease (right image, white arrow on the fused ^{68}Ga -PSMA PET/CT)

Figure 4



A 68-year-old man who had Gleason 3+4 disease treated with prostatectomy and prostate bed RT a year later. Now with a rising PSA (1.24), ⁶⁸Ga-PSMA PET/MRI revealed small volume presacral nodes which were tracer avid.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

The upper image is an axial T2 HASTE MRI image with the white arrow indicating a small volume lymph node (4mm in short axis diameter). The lower image is a fused T2 HASTE and ⁶⁸Ga-PSMA attenuation corrected image showing the small node is PSMA avid.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65